Abstracts tagged "Health Services Research"

Abstract Number: 0179 • ACR Convergence 2025
Digital Divide in Rheumatology: Patterns of Technology and AI Adoption Across Generations of Specialists
CARLA F DIONELLO¹, ANA F PADUA², Claudia Marques³, BRUNA L PORTO⁴, LEONARDO R CAMPOS⁵, RODRIGO OLIVEIRA⁶, GUSTAVO GM BALBI⁷, RODRIGO LUPPINO-ASSAD⁶, YURE G AZEVEDO⁸, LUIZ F DIPE⁹, BRUNO BORDALLO⁵, Cleandro Pires¹⁰, Licia Maria Henrique da Mota¹⁰ and PAULA MONTINA¹⁰, ¹FEDERAL UNIVERSITY OF RIO DE JANEIRO - UFRJ, RIO DE JANEIRO, Rio de Janeiro, Brazil, ²SANTA CASA MG, BELO HORIZONTE, Minas Gerais, Brazil, ³Hospital das Clinicas - Universidade Federal de Pernambuco - UFPE, Recife, Pernambuco, Brazil, ⁴UNIVATES, SÃO LEOPOLDO, Rio Grande do Sul, Brazil, ⁵UFF, Rio de Janeiro, Rio de Janeiro, Brazil, ⁶FMRP-USP, Ribeirão Preto, Sao Paulo, Brazil, ⁷UFJF, JUIZ DE FORA, Minas Gerais, Brazil, ⁸SCR, SOBRAL, Ceara, Brazil, ⁹GRUPO AMIL, SÃO PAULO, Sao Paulo, Brazil, ¹⁰UNB, Brasilia, Distrito Federal, Brazil
Background/Purpose: The integration of digital tools and artificial intelligence (AI) in rheumatology practice has advanced rapidly. However, disparities in adoption across generations of specialists remain…
Abstract Number: 1932 • ACR Convergence 2025
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Bryant England³, Emily Leasure¹, Elena myasoedova¹, John Davis¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Nebraska Medical Center, Omaha, NE, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death.…
Abstract Number: 1259 • ACR Convergence 2025
Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
Angelo Gaffo¹, Bhavisha Desai², Abiola Oladapo³, Nana Kragh⁴, Rebekah Zincavage⁵, Brad Padilla⁵ and Naomi Schlesinger⁶, ¹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ²Sobi, Glastonbury, CT, ³Sobi INC, Waltham, MA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Stratevi, Boston, ⁶Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT
Background/Purpose: Many patients with uncontrolled gout (UG) experience symptoms despite being on urate-lowering therapy (ULT), often requiring support from informal caregivers. UG impacts patients and…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 0177 • ACR Convergence 2025
Artificial intelligence in adult and paediatric rheumatology practice and research: pilot results from an international survey
Ana Isabel Rebollo-Gimenez¹, Saverio La bella², Krystel Aouad³, Latika Gupta⁴, Davide Cangelosi⁵, Thomas Högle⁶, Johannes Knitza⁷, Nicolino Ruperto⁸, Vincenzo Venerito⁹, Abdellah El Maghraoui¹⁰, Alessandra Alongi¹¹, Wilson bautista molano¹², Deniz Bayraktar¹³, Thomas Davergne¹⁴, Dzifa Dey¹⁵, Ihsane Hmamouchi¹⁶, Alison Hoens¹⁷, Linda Li¹⁷, Angela Migowa¹⁸, Erin Treemarcki¹⁹, Nelly Ziade²⁰, Tue Kragstrup²¹ and Diego Benavent²², ¹Department of Rheumatology, Gregorio Marañon University Hospital, Gregorio Marañon Health Research Institute, Madrid, Spain, ²UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ³Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, ⁴School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁵Unità di Bioinformatica Clinica, Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁶Department of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland, ⁷Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, ⁸Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ⁹Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁰Department of Rheumatology, Military Hospital Mohammed V, Rabat, Morocco, ¹¹Università Milano Bicocca, Milano, MILAN, Italy, ¹²University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ¹³Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Izmir Katip Celebi University. Arthritis Research Canada, Vancouver, British Columbia., Izmir, Turkey, ¹⁴Department of rehabilitation.Team METHODS, CRESS UMR ¹¹⁵³ – University of Paris Cité, Paris, France, ¹⁵Rheumatology Unit Department of Medicine and Therapeutics, Korle bu Teaching Hospital, University of Ghana Medical School, Accra, Ghana, ¹⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ¹⁷Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ¹⁸Aga Khan University Medical College East Africa, Nairobi, Kenya, ¹⁹Department of Pediatrics, Division of Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ²⁰Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ²¹Department of Biomedicine, Aarhus University & Rheumatology Sector, Medical Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Aarhus C, Denmark, ²²Hospital Universitari de Bellvitge, Madrid, Spain
Background/Purpose: Artificial intelligence (AI) is transforming rheumatology care, with innovative tools now empowering physicians and health professionals (HPRs). Our survey examines how adult and pediatric…
Abstract Number: 1929 • ACR Convergence 2025
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
Michael Marrone¹, Christopher McPherson² and Abiola Oladapo³, ¹Sobi Inc., Mt Pleasant, SC, ²Sobi, University City, MO, ³Sobi INC, Waltham, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of rheumatologic disease. MAS is a form of secondary hemophagocytic lymphohistiocytosis which occurs most frequently…
Abstract Number: 1257 • ACR Convergence 2025
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Puneet Bajaj², Urooj Wahid², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Rheumatic diseases (RD) often cause pain, fatigue and disability. Depression and anxiety are prevalent comorbidities in RD and ideally managed with behavioral health (BH)…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 0178 • ACR Convergence 2025
Prevalence and factors associated with virtual rheumatology care utilization in a national population of Veterans with RA
Beth Wallace¹, Yuqing Gao², Shirley Cohen-Mekelburg² and Akbar Waljee², ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare Center, Ann Arbor
Background/Purpose: Up to half of RA patients receive virtual rheumatology care, which is associated with high satisfaction but potentially lower quality. We aimed to identify…
Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Joshua Skydel¹, Anna Leland², Reshma Ramachandran³, Fotios Koumpouras³ and Joshua Wallach², ¹Yale-New Haven Hospital, New Haven, CT, ²Rollins School of Public Health, Atlanta, GA, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
Abstract Number: 1256 • ACR Convergence 2025
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Urooj Wahid², Puneet Bajaj², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Patients with rheumatic diseases (RD) often experience chronic pain, along with comorbid depression and anxiety, which can be addressed using behavioral health (BH) interventions…
Abstract Number: 0602 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Ami Vyas¹, Steven Cohen² and Christine Eisenhower², ¹University of Rhode Island, Kingston, RI, ²University of Rhode Island, Kingston
Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…
Abstract Number: 0158 • ACR Convergence 2025
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Lesley Jackson¹, jerrod anzalone², Rahima Begum³, Fazlur Rahman¹, Namrata Singh⁴, Londyn Robinson⁵, Kaleb Michaud², Kenneth Saag⁶, Jasvinder Singh⁷, Rena Patel¹ and Maria I. ("Maio") Danila⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Washington, Bellevue, WA, ⁵University of Washington, Seattle, WA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Baylor College of Medicine, Houston, TX, ⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
Abstract Number: 1924 • ACR Convergence 2025
Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
Joseph Yang¹, Katy Sadowski¹, Akshay Kharat¹, Ann Chauffe¹ and Tejaswini Kulkarni², ¹Boehringer Ingelheim, Ridgefield, CT, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a group of autoimmune diseases that affect multiple organ systems, including the lungs. The development of interstitial lung…
Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Rosemary Hollick¹, Marcus Beasley¹, Ernest Choy², Caroline Cupit³, Debra Dulake¹, Teresa Finlay³, Louise Locock¹, Paul McNamee¹, Catherine Pope³, Elaine Wainwright¹, David Williams⁴ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University of Michigan, Michigan
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].